Background: Idiopathic pulmonary fibrosis (IPF) is a rapidly lethal disease characterized by
anarchic, progressive fibrosis. Pulmonary fibrosis is the result of interactions between many …

Idiopathic pulmonary fibrosis (IPF) is a debilitating, fatal, chronic fibrosing lung disease with
no known effective therapy. Endothelin-1 may underlie the pathogenesis of lung fibrosis …

Diseases with pulmonary fibrosis belong to the group of fibrosing interstitial lung diseases
(ILD). Idiopathic pulmonary fibrosis (IPF) characterized by a histopathologic pattern of usual …

Endothelin is one of a number of profibrotic cytokines and growth factors, along with
transforming growth factor-β, connective tissue growth factor and tumour necrosis factor-α …

Idiopathic pulmonary fibrosis (IPF) is a chronic condition of unknown aetiology with
deteriorating respiratory function leading to respiratory failure. Sequential acute lung injury …

Accumulating evidence suggests that idiopathic pulmonary fibrosis (IPF) results from lung
injury primarily following an abnormal wound healing response towards epithelial cell …

PURPOSE: Endothelin-1 is a potent vasoconstrictor but also can promote fibrosis, cell
proliferation and remodeling. Bosentan, an ETA and ETB receptor antagonist, has …

The endothelin system participates in a number of critical biologic pathways, including
normal wound healing. In addition, emerging basic science, and animal and human data all …

Idiopathic pulmonary fibrosis (IPF) is a fatal disease for which no effective treatment exists. In
the present study, 12 IPF patients underwent analysis of gas exchange properties using the …

Rationale: A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend
to delayed IPF worsening or death. Also, improvements in some measures of dyspnea and …